- Home
- Publications
- Publication Search
- Publication Details
Title
Cognitive impairment in schizophrenia: the great unmet need
Authors
Keywords
-
Journal
CNS SPECTRUMS
Volume 20, Issue S1, Pages 32-40
Publisher
Cambridge University Press (CUP)
Online
2015-12-18
DOI
10.1017/s109285291500070x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Second-generation antipsychotic effect on cognition in patients with schizophrenia-a meta-analysis of randomized clinical trials
- (2015) R. E. Nielsen et al. ACTA PSYCHIATRICA SCANDINAVICA
- Cognitive Enhancement Treatment for People With Mental Illness Who Do Not Respond to Supported Employment: A Randomized Controlled Trial
- (2015) Susan R. McGurk et al. AMERICAN JOURNAL OF PSYCHIATRY
- Can computer-assisted cognitive remediation improve employment and productivity outcomes of patients with severe mental illness? A meta-analysis of prospective controlled trials
- (2015) Joyce Y.C. Chan et al. JOURNAL OF PSYCHIATRIC RESEARCH
- Glutamate and dopamine in schizophrenia: An update for the 21st century
- (2015) Oliver Howes et al. JOURNAL OF PSYCHOPHARMACOLOGY
- The muscarinic system, cognition and schizophrenia
- (2015) Sean P. Carruthers et al. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
- Emerging drugs for schizophrenia: an update
- (2014) Luisa-Sophie Köster et al. EXPERT OPINION ON EMERGING DRUGS
- Safety and clinical effects of EVP-6124 in subjects with Alzheimer's disease currently or previously receiving an acetylcholinesterase inhibitor medication
- (2014) William James Deardorff et al. Expert Review of Neurotherapeutics
- Unmet Needs in the Treatment of Schizophrenia
- (2014) Leslie Citrome JOURNAL OF CLINICAL PSYCHIATRY
- A Randomized Controlled Trial of Cognitive Remediation Among Inpatients With Persistent Mental Illness
- (2014) Jean-Pierre Lindenmayer et al. PSYCHIATRIC SERVICES
- The novel α7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens
- (2014) Mei Huang et al. PSYCHOPHARMACOLOGY
- Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia
- (2013) Jared W. Young et al. BIOCHEMICAL PHARMACOLOGY
- Reliability and validity of the Personal and Social Performance scale in patients with schizophrenia
- (2012) Beenish Nafees et al. SCHIZOPHRENIA RESEARCH
- Cognitive Remediation in Schizophrenia
- (2012) Yoshio Kaneko et al. Clinical Psychopharmacology and Neuroscience
- EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors
- (2011) Jos Prickaerts et al. NEUROPHARMACOLOGY
- Muscarinic and Nicotinic Acetylcholine Receptor Agonists and Allosteric Modulators for the Treatment of Schizophrenia
- (2011) Carrie K Jones et al. NEUROPSYCHOPHARMACOLOGY
- Cognition in schizophrenia: core psychological and neural mechanisms
- (2011) Deanna M. Barch et al. TRENDS IN COGNITIVE SCIENCES
- N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: The final common pathway on the road to schizophrenia?
- (2010) Joshua T. Kantrowitz et al. BRAIN RESEARCH BULLETIN
- The treatment of cognitive impairment in schizophrenia
- (2010) Donald C. Goff et al. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
- Vocational, Social, and Cognitive Rehabilitation for Individuals Diagnosed With Schizophrenia: A Review of Recent Research and Trends
- (2010) Seth Kurzban et al. Current Psychiatry Reports
- The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway
- (2009) O. D. Howes et al. SCHIZOPHRENIA BULLETIN
- The MATRICS Consensus Cognitive Battery, Part 1: Test Selection, Reliability, and Validity
- (2008) Keith H. Nuechterlein et al. AMERICAN JOURNAL OF PSYCHIATRY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started